The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
β-Blocker Use, BMD, and Fractures in the Study of Osteoporotic Fractures
Open accessAbstract
A role for osteoblastic β-adrenoreceptors in bone regulation is suggested by the finding that β-blockers increase bone mass in mice. We studied the association of β-blocker use with BMD and fractures in the Study of Osteoporotic Fractures. β-blocker use and BMD are unrelated in this cohort, and associations with fracture risk are inconsistent. Introduction: The central nervous system has been shown to regulate bone mass in mice, possibly by way of the β2-adrenoreceptors on osteoblasts. β-blockers have been shown to increase bone mass in mice. Because these agents are widely used therapeutically, it is possible that they may influence fracture epidemiology in humans, and they are a potential therapy for osteoporosis. Materials and Methods: We have studied the association of β-blocker use with BMD and fracture rates in the Study of Osteoporotic Fractures. β-blocker use was recorded at the fourth visit, in 8412 women, of whom 1099 were users, and these women were followed for 7 years. Results: Users had significantly higher weight, more thiazide use, more estrogen use, less glucocorticoid use, more statin use, and more hypertension than nonusers, and they smoked less. Total hip BMD at the fourth visit was higher in the β-blocker users (0.746 versus 0.735 g/cm2, p = 0.02), but adjustment for weight alone, or together with these other variables, eliminated this difference (p = 0.62). There was no effect of β-blocker use on loss of hip BMD over a mean follow-up of 4 years (p = 0.48). Os calcis BMD at visit 4 was also higher in those taking β-blockers (0.385 versus 0.375 g/cm2, p = 0.005), but weight adjustment eliminated this difference (p = 0.14). The frequencies of hip or any fracture (since age 50) were similar in users and nonusers (p = 0.80 and p = 0.51, respectively). Over a mean follow-up of 7 years, there were 2167 total fractures, including 431 at the wrist and 585 at the hip. Among β-blocker users, hazards ratios were 0.92 (0.81, 1.05) for any fracture, 0.74 (0.54, 1.01) for wrist fracture, and 0.76 (0.58, 0.99) for hip fracture. Adjustment for weight and other factors previously shown to influence hip fracture incidence in this cohort made little difference to the outcome. When fracture data were analyzed for nonselective and β1-selective agents separately, trends toward fewer fractures were confined to the users of selective β1-blockers. Conclusions: β-blocker use and BMD are unrelated in this cohort, and associations with fracture risk are inconsistent. Therefore, a history of use of these drugs is not useful in assessing fracture risk, nor do they have a role in osteoporosis management at this time. The relationship between β-blocker use and hip fracture deserves further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Leptin deficiency or resistance is associated with high BMD in mice despite the fact that gonadal function is diminished (103).”
From Pathogenesis of osteoporosis: concepts, conflicts, and prospects (2005) · cites this paper as [103]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leptin Inhibits Bone Formation through a Hypothalamic Relay
Ducy, P., Amling, M., Takeda, S., Priemel, M., Schilling, A. F., Beil, F. T., Shen, J., Vinson, C., Rueger, J. M., & Karsenty, G. (2000) · Cell · doi:10.1016/s0092-8674(00)81558-5 · Cited by 2,077
Leptin Regulates Bone Formation via the Sympathetic Nervous System
Takeda, S., Elefteriou, F., Levasseur, R., Liu, X., Zhao, L., Parker, K. L., Armstrong, D., Ducy, P., & Karsenty, G. (2002) · Cell · doi:10.1016/s0092-8674(02)01049-8 · Cited by 1,735
Cauley, J. A. (2003) · JAMA · doi:10.1001/jama.290.13.1729 · Cited by 1,229
Pasco, J. A., Henry, M. J., Sanders, K. M., Kotowicz, M. A., Seeman, E., & Nicholson, G. C. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301214 · Cited by 260
Effects of neonatal sympathectomy and capsaicin treatment on bone remodeling in rats
Hill, E. L., Turner, R. T., & Elde, R. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90094-5 · Cited by 187
Reid, I. R., Ames, R. W., Orr‐Walker, B., Clearwater, J. M., Horne, A. M., Evans, M. C., Murray, M. A. F., McNeil, A. R., & Gamble, G. D. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00510-6 · Cited by 179
Self-citationMoore, R. E. B., Smith, C. K., Bailey, C. S., Voelkel, E. F., & Tashjian, A. H. (1993) · Bone and Mineral · doi:10.1016/s0169-6009(08)80105-5 · Cited by 175
Cherruau, M., Facchinetti, P., Baroukh, B., & Jl, S. (1999) · Bone · doi:10.1016/s8756-3282(99)00211-2 · Cited by 144
Takeuchi, T., Tsuboi, T., Arai, M., & Togari, A. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00591-8 · Cited by 139
Intermittent Use of Nitrates Increases Bone Mineral Density: The Study of Osteoporotic Fractures
Jamal, S. A., Browner, W. S., Bauer, D. C., & Cummings, S. R. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.11.1755 · Cited by 131
Self-citation
Cited by
Sorted by citations
Items 101–155 of 155
Sessa, M., Mascolo, A., Rasmussen, D. B., Kragholm, K. H., Jensen, M. T., Sportiello, L., Rafaniello, C., Tari, G. M., Pagliaro, C., Andersen, M. T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47967-y · Cited by 7
Baek, K., Kang, J., Lee, J., Kim, M., & Baek, J. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0407-3 · Cited by 7
Teki̇n, S., Dündar, S., Demirci, F., Bozoğlan, A., Yıldırım, T. T., Karaman, T., & Gül, M. (2020) · Journal of Craniofacial Surgery · doi:10.1097/scs.0000000000006959 · Cited by 7
Iwase, S., Nishimura, N., & Mano, T. (2013) · InTech eBooks · doi:10.5772/54708 · Cited by 9
Leptin, central nervous system, and bone: influence of physical activity
Bonnet, N., Courteix, D., & Benhamou, C. L. (2005) · Joint Bone Spine · doi:10.1016/j.jbspin.2005.10.001 · Cited by 7
Compston, J. E. (2013) · Primer on the metabolic bone diseases and disorders of mineral metabolism · doi:10.1002/9781118453926.ch64 · Cited by 7
Liu, L., Wang, Y., Tan, B., & Huang, P. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07471-8 · Cited by 6
A systems approach to bone pathophysiology
Weiss, A., Lipshtat, A., & Mechanick, J. I. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05816.x · Cited by 6
Alawy, R. A., Hammad, H., & Habashneh, R. A. (2019) · Clinical Oral Investigations · doi:10.1007/s00784-019-02987-w · Cited by 6
Chapter 10. Neuronal Regulation of Bone Remodeling
Karsenty, G., & Elefteriou, F. (2008) · Wiley eBooks · doi:10.1002/9780470623992.ch10 · Cited by 5
Evaluation of antihypertensive drug-induced changes in mandibular bone using fractal analysis
Aşantoğrol, F., & Koruyucu, A. N. (2024) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2024.08.015 · Cited by 5
Lezón, C. E., Pintos, P. M., Olivera, M. I., Bozzini, C., & Boyer, P. M. (2011) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2011.09.006 · Cited by 5
Maytalman, E., Yegani, A. A., Kozanoğlu, İ., & Aksu, F. (2021) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2021.1957931 · Cited by 5
Hypertension, Antihypertensive Drugs, and Bone Mineral Density
Hwang, J. K., Leu, R., & Butt, D. A. (2015) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-015-9193-x · Cited by 5
Interactions between bone tissue and energy metabolism
Confavreux, C. B. (2010) · Joint Bone Spine · doi:10.1016/j.jbspin.2010.04.013 · Cited by 5
Lezón, C. E., Pintos, P. M., Olivera, M. I., Bozzini, C., & Boyer, P. M. (2012) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2011.09.005 · Cited by 4
Pathophysiology and evaluation of bone health in adrenal diseases
Uygur, M. M., di Filippo, L., Frara, S., Menotti, S., & Giustina, A. (2025) · Endocrine · doi:10.1007/s12020-025-04260-5 · Cited by 4
Do effects of propranolol on the skeletal system depend on the estrogen status?
Śliwiński, L., Folwarczna, J., Pytlik, M., Cegieła, U., Nowińska, B., Trzeciak, H., & Trzeciak, H. I. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71493-2 · Cited by 4
Endocrinology of bone/brain crosstalk
Metozzi, A., Bonamassa, L., Brandi, G., & Brandi, M. L. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.979787 · Cited by 4
Skripnikova, I. A., Арсланалиевна, А. Н., Kolchina, М. А., Myagkova, M. A., & Косматова, О. В. (2019) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2019-15-1-69-76 · Cited by 4
Contrôle central de la masse osseuse : implications thérapeutiques potentielles
Levasseur, R., Legrand, É., Chappard, D., & Audran, M. (2005) · Revue du Rhumatisme · doi:10.1016/j.rhum.2005.09.004 · Cited by 3
Hernández, J. L., & Valero, C. (2015) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-015-9186-9 · Cited by 3
Pharmacogenomic Effects of β-Blocker Use on Femoral Neck Bone Mineral Density
Nevola, K. T., Nagarajan, A., Hinton, A. C., Trajanoska, K., Formosa, M. M., Xuereb‐Anastasi, A., van der Velde, N., Stricker, B. H. C., Rivadeneira, F., Fuggle, N. R., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab092 · Cited by 3
Qiu, J., Xu, J., Cai, Y., Li, M., Peng, Y., Xu, Y., & Chen, G. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1295429 · Cited by 3
Leptina y hueso: mecanismos moleculares de la interacci n leptina-osteoblasto
Gómez, J. M. Q. (2006) · Revista Española de Enfermedades Metabólicas Óseas · doi:10.1016/s1132-8460(06)75255-2 · Cited by 3
Regulation of Bone Remodeling by Central and Peripheral Nervous Signals
Takeda, S., & Ducy, P. F. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00016-1 · Cited by 2
The Cross Talk Between the Central Nervous System, Bone, and Energy Metabolism
Wei, J., & Karsenty, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804182-6.00019-8 · Cited by 2
Anumas, S., Thitisuriyarax, S., Tantiyavarong, P., Pholsawatchai, W., & Pattharanitima, P. (2023) · Medicina · doi:10.3390/medicina59010129 · Cited by 2
The Aging Skeleton: Differences Between HIV-Infected Patients and the Uninfected Aging Population
Guaraldi, G., Santoro, A., & da Silva, A. R. D. (2012) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-012-9138-6 · Cited by 1
Lim, K. K., Ang, H. T., Kwan, Y. H., Tan, C. S., Østbye, T., & Low, L. L. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0608-5 · Cited by 1
An Investigation of Diabetes Mellitus in Postmortem Human Remains
May, S. E. (2014) · Cited by 1
Regulation of bone remodeling by central and peripheral nervous signals
Ducy, P. F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00034-8 · Cited by 1
Mundy, G. R., Oyajobi, B. O., Gutierrez, G., Sterling, J. A. R., Padalecki, S. S., Elefteriou, F., & Zhao, M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-375098-3.50019-6 · Cited by 1
Chapter 64. Skeletal Effects of Drugs
Compston, J. E. (2008) · Primer on the metabolic bone diseases and disorders of mineral metabolism · doi:10.1002/9780470623992.ch64 · Cited by 1
Leptin regulation of bone mass by the sympathetic nervous system and CART
Hamrick, M. W. (2005) · BoneKEy-Osteovision · doi:10.1138/20050166 · Cited by 1
Leptine, système nerveux central et tissu osseux : influence de l'exercice physique
Bonnet, N., Courteix, D., & Benhamou, C. L. (2005) · Revue du Rhumatisme · doi:10.1016/j.rhum.2005.09.002 · Cited by 1
de Vries, F., Souverein, P. C., Cooper, C. C., Leufkens, H. G. M., & van Staa, T. P. (2007) · Cited by 1
Leptin and Bone Central control of bone metabolism by leptin
Takeda, S. (2006) · Springer eBooks · doi:10.1007/978-0-387-31416-7_8
Martins, G. M. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2013.tde-12062013-083322
Interactions entre tissu osseux et métabolisme énergétique
Confavreux, C. B. (2010) · Revue du Rhumatisme · doi:10.1016/j.rhum.2010.03.017
Pérez‐Castrillón, J. L., Vega, G., Abad, L., Sanz, A., Mendo, M., García-Porrero, M., & Dueñas, A. (2007) · Revue du Rhumatisme · doi:10.1016/j.rhum.2006.09.016
Preliminary Assessment of Tc-Salmeterol Xinafoate as a Potential Bone Imaging Agent
Zaghary, W. A., Motaleb, M. A., & Anwar, M. M. (2016) · The Open Conference Proceedings Journal · doi:10.2174/2210289201607010080
Macedo, F. A. F. F., Nunes, E. H. M., Vasconcelos, W. L., Santos, R. A. S., Sinisterra, R. D., & Cortés, M. E. (2012) · DOAJ (DOAJ: Directory of Open Access Journals)
EFFECT OF BETA-BLOCKERS ON BONE MINERAL DENSITY AND OSTEOPOROTIC FRACTURES
Собченко, К. Е., Skripnikova, I. A., Абирова, Э. С., & Птичкина, П. А. (2013) · Osteoporosis and Bone Diseases · doi:10.14341/osteo2013135-38
Chapter 51 – Diuretics and β-Blockers
Hall, A., Dobbie, H., Capasso, G., & Unwin, R. (2008) · Elsevier eBooks · doi:10.1016/b978-141605484-9.50053-8
Central Neural Control of Bone
Ducy, P. F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11225-5
Systemic medications and implant success
Sukumaran, P., Dionysius, D. D., Ngeow, W. C., Tan, C. C., & Hussin, M. Z. (2022) · Journal of Dental Implants · doi:10.4103/jdi.jdi_22_21
The central regulation of bone remodeling
Karsenty, G., & Ducy, P. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13683-2.00025-6
Mécanismes moléculaires du contrôle de la masse musculaire sous l'action du β2-agoniste formotérol
Joassard, O. (2013) · theses.fr (ABES) · doi:10.70675/251c01fcz1479z415aza11cz70e69f50a189
Bone microarchitectural degradation in hypertensive patients: a population-based study
Bioletto, F., Bollati, M., Barale, M., Lopez, C., Pusterla, A., Arvat, E., Ghigo, E., Maccario, M., Massimo, P., & Parasiliti‐Caprino, M. (2026) · Archives of Osteoporosis · doi:10.1007/s11657-026-01703-y
Virdis, A. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/6773898
Sato, T., Miyazawa, K., Tabuchi, M., & Ogawa, T. (2026) · Materials Today Advances · doi:10.1016/j.mtadv.2026.100913
Huang, C., Kuang, S., Chen, X., Fu, S., Wang, G., Li, Y., Tan, H., & Zhang, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1908275
Metadata
- Authors
- Reid, I. R., Gamble, G. D., Grey, A. B., Black, D. M., Ensrud, K. E., Browner, W. S., & Bauer, D. C.
- Affiliations
- University of Auckland (NZ)
- Department of Medicine, University of Auckland, Auckland, New Zealand
- University of California, San Francisco (US)
- University of Minnesota (US)
- Corresponding author
- Reid, Ian R
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-04-01
- Volume
- 20
- Issue
- 4
- Pages
- 613-618
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2046327104
- Cited by
- 156
- References
- 19
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 6 · 2018: 7 · 2017: 2 · 2016: 5 · 2015: 9 · 2014: 3 · 2013: 13 · 2012: 14
- FWCI
- 17.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service
- Health Research Council of New Zealand
- National Institute on Aging (AG05394, AG-05407)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR035584, AR35583, AR-35584, AR 35582, R01AR035582, R01AR035583)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- beta-blockers, bone mineral density, osteoporotic fractures, hip fracture, wrist fractures, bone mass regulation, Study of Osteoporotic Fractures, women, thiazide diuretics, glucocorticoids, estrogen use, statins, hypertension, osteoporosis treatment, fracture risk factors
- MeSH terms
- Adrenergic beta-Antagonists, Aged, Bone and Bones, Female, Fractures, Spontaneous, Humans, Osteoporosis, Bone Density, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
